

Advanced Magnetix (Cambridge, MA, USA) has appointed **Michael N. Avallone** as CFO. He assumes the responsibilities of vice president of finance **James A. Matheson**, who is stepping down to focus on other opportunities. Mr. Avallone was most recently vice president of finance and CFO of Boston Biomedica.

Nuvelo (Sunnyvale, CA, USA) has named **Lee Bendekgey** senior vice president and general counsel. He joins Nuvelo from Incyte, where he held several positions, including executive vice president, general counsel, acting chief financial officer and acting general manager of information business.

Corgentech (S. San Francisco, CA, USA) has appointed **Patrick Broderick** as vice president, general counsel and corporate secretary. Mr. Broderick was previously vice president, secretary and general counsel of DaVita, and general counsel for COR Therapeutics.

Sean Darragh has been named executive director of the food and agriculture section of the Biotechnology Industry Organization (Washington, DC, USA), a newly created position. He was most recently deputy vice president of international affairs at the Pharmaceutical Research and Manufacturers of America, and has served in a number of senior positions in the US government, including principal deputy assistant secretary of defense at the Pentagon and principal negotiator at the Office of the US Trade Representative.



Sijmen de Vries has been appointed CEO of Morphochem (Munich, Germany). Dr. de Vries served most recently as head of global business development and licensing for

Novartis Ophthalmics. Other past positions include CEO of the Rademacher Group, a biotech startup, and director of market development, Europe at SmithKline Beecham.

David A. Ferrick has been named to the position of vice president, biology and clinical applications at Guava Technologies (Hayward, CA, USA). Dr. Ferrick was previously CEO and a director of Sagres Discovery.

Neuromed Technologies (Vancouver, BC, Canada) has named **Christopher Gallen** president, CEO and a member of the board of directors. Dr. Gallen was most recently vice president and chief of operations, clinical research and development at Wyeth Research.

Linguagen (Cranbury, NJ, USA) has appointed **Scott M. Horvitz** to the position of CFO. Mr. Horvitz cofounded 3-Dimensional Pharma-

ceuticals in 1993, most recently serving as its CFO and corporate secretary and treasurer.

Acambis (Cambridge, UK) has announced the appointment of **David Lawrence** as CFO. He was most recently vice president of finance for Chiron Vaccines, and previously spent 13 years at GlaxoSmithKline and its predecessor companies. He left GSK in 2001 to become CFO of privately held Strakan Pharmaceuticals.

Cetek (Marlborough, MA, USA) has announced that **Byron Long** has joined the company as director of oncology research. Dr. Long was most recently a senior principal scientist in oncology biology at the Bristol-Myers Squibb Pharmaceutical Research Institute.

Avidis (Clermont Ferrand, France) has appointed to its management committee **François Miceli**, CEO, **Fergal Hill**, executive director, research and intellectual property, and **Michel Wurm**, executive director of business and pre-clinical development.

Osiris Therapeutics (Baltimore, MD, USA) has appointed **C. Randal Mills** president, CEO and a member of the board of directors. Dr. Mills was a cofounder of Regeneration Technologies, and served in several positions including vice president of business development and vice president of operations.

David Moran and **John Brown** have been named nonexecutive directors at Ardana (Edinburgh, UK). Dr. Moran was SmithKline Beecham's vice president of worldwide clinical operations until 1993, and was a principal associate at Mansford Associates, a private healthcare consultancy. Dr. Brown was CEO of Acambis from 1997 until late 2003, and currently chairs the governing council of the Roslin Institute.

André Pernet has been named as an associate member at life science advisers Bionest Partners (Paris), where he will focus on technology assessment and management for pharmaceutical and biotechnology companies. Dr. Pernet was previously a corporate officer and vice president, pharmaceutical products R&D with Abbott Laboratories. From 2000 to 2002, he served as chairman and CEO of Genset, and currently holds directorships at Quark Biotech, Kaleidos Pharmaceuticals and ViroChem.

Cellomics (Pittsburgh, PA, USA) has announced the appointment of **William T. Sharp** as vice president, business development. He joins the company from Genentra Systems, where he served in the same position. Before that, Mr. Sharp spent six years with Life Technologies/Invitrogen managing its molecular biology business and new business initiatives.